Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel
Portfolio Pulse from
Precision Biosciences' ARCUS platform and TG Therapeutics' BRIUMVI are making strides in gene editing and sales growth, respectively. DTIL is rated a speculative 'Buy' due to its promising pipeline, while TGTX is rated 'Hold' due to full valuation.
March 15, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow. TGTX is rated 'Hold' due to its full valuation.
Despite BRIUMVI's sales growth, TGTX's full valuation leads to a 'Hold' rating, indicating limited short-term upside.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Precision Biosciences' ARCUS platform supports gene editing therapies and has strategic partnerships for azer-cel's development. DTIL is rated a speculative 'Buy' due to its undervaluation and promising pipeline.
The ARCUS platform's capabilities and strategic partnerships enhance DTIL's growth prospects, justifying the 'Buy' rating despite its speculative nature.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80